Related Experiment Video

Updated: Nov 24, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.5K

Relation between neutrophil-to-lymphocyte ratio and mortality in patients with hypertrophic cardiomyopathy

Ziqiong Wang1, Liming Zhao2, Sen He1

  • 1Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.

Biomarkers in Medicine
|December 21, 2020
PubMed

Insights

The neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for all-cause mortality in hypertrophic cardiomyopathy (HCM) patients. Higher NLR levels correlate with increased mortality risk in individuals with HCM.

Area of Science:

  • Cardiology
  • Biomarkers

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease.
  • Identifying prognostic markers for mortality in HCM is crucial for patient management.

Purpose of the Study:

  • To evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) for all-cause mortality in patients diagnosed with HCM.

Main Methods:

  • A cohort of 354 patients with HCM was analyzed.
  • Neutrophil-to-lymphocyte ratio (NLR) levels were assessed.
  • All-cause mortality was tracked over the study period.

Main Results:

  • The third tertile of NLR exhibited the highest all-cause mortality rate (5.2 per 100 person-years).
  • Patients in the highest NLR tertile demonstrated a significantly increased risk of all-cause mortality (adjusted hazard ratio: 2.4; 95% CI: 1.0-5.4; p=0.040).
  • Subgroup analyses revealed no significant interactions between NLR and other clinical variables.

Conclusions:

  • The neutrophil-to-lymphocyte ratio (NLR) serves as an independent predictor of all-cause mortality in patients with hypertrophic cardiomyopathy (HCM).
  • NLR may aid in risk stratification and clinical decision-making for HCM patients.

Keywords:
all-cause mortalityhypertrophic cardiomyopathyinflammationneutrophil-to-lymphocyte ratio

More Related Videos

A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation07:14

A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation

Published on: July 13, 2018

14.8K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.4K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
164
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
127
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
355
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
142
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
169
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
383